Research Article

Ethanol Extract of Ulmus pumila Root Bark Inhibits Clinically Isolated Antibiotic-Resistant Bacteria

Yong-Ouk You, 1,2 Na-Young Choi, 3 and Kang-Ju Kim 2,4

1 Department of Oral Biochemistry, School of Dentistry, Wonkwang University, Iksan 570-749, Republic of Korea
2 Wonkwang Research Institute for Food Industry, Iksan 570-749, Republic of Korea
3 College of Education, Wonkwang University, Iksan 570-749, Republic of Korea
4 Department of Oral Microbiology, School of Dentistry, Wonkwang University, Iksan 570-749, Republic of Korea

Correspondence should be addressed to Kang-Ju Kim; kaob@wku.ac.kr

Received 1 August 2013; Accepted 3 September 2013

1. Introduction

Staphylococcus aureus (S. aureus) is one of the most common bacteria in humans. S. aureus is normally present in the skin, nasal cavity, or laryngopharynx of healthy men and opportunistically causes a local or systemic infection [1, 2]. However, S. aureus is a causative bacteria of nosocomial infection and occupies more than 80% of pyogenic infection such as abscess and septicemia [2–5].

Penicillin was developed in 1941 and has been used as a therapeutic agent indicated for bacterial infections. Since then, numerous antibiotic agents have been developed and are effective against bacterial infections, but the appearance of antibiotic-resistant bacterial strains caused a big problem in the treatment of patients [6, 7]. The appearance of such antibiotic-resistant bacterial strains tends to increase due to the overuse of antibiotics. Antibiotic-resistant strains which became an important issue in the world include methicillin-resistant Staphylococcus aureus (MRSA) [8]. These bacteria strains have multidrug resistance showing resistance to various antibiotic agents such as β-lactams, or aminoglycosides. Treatment of patients infected with these bacterial strains is known to be very difficult [9, 10], so MRSA is one of the important causes of modern chronic infectious diseases. It is known that the resistance mechanisms of MRSA to methicillin include (1) production of β-lactamase, which inactivate the β-lactam antibiotics and (2) the possession of mecA gene that produces penicillin-binding proteins, such as PBP, PBP2', or PBP2a, which have low affinity to β-lactam antibiotics [7]. Since MRSA shows resistance to various antibiotics, it is necessary to develop new substances for the treatment of MRSA. Several natural substances may be candidates for new antibiotic substances [11]. We have explored natural substances with antimicrobial effects on MRSA [12–14].

Ulmus pumila (U. pumila) is a natural herb that has traditionally been used for the treatment of infections in Korea. U. pumila, belonging to the botanical classification...
of Ulmaceae, is distributed in Korea, Japan, northern China, Sakhalin, and East Siberia. This tree grows to 15 meters and its bark is dark brown in color. Owing to its antibacterial and anti-inflammatory reaction, *U. pumila* has been traditionally used for abscess, infection, edema, rhinitis, empyema, and otitis media. It has also been used for gastric and duodenal ulcers as well as gastric cancer [15–17].

In this study, *U. pumila* was extracted with ethanol, and then the antimicrobial effects of *U. pumila* ethanol extract were tested on clinically isolated 12 MRSA strains and 1 standard MRSA strain, and phytochemical analysis was performed.

### 2. Materials and Methods

#### 2.1. Plant Material and Extraction

The bark of *U. pumila* was obtained from the oriental drug store, Dae Hak Yak Kuk (Iksan, South Korea). The identity was confirmed by Dr. Bong-Seop Kil at the Department of Natural Science, Wonkwang University.

Voucher specimen (number 09-03-26) has been deposited at the Herbarium of Department of Oral Biochemistry in Wonkwang University. Dried bark of *U. pumila* (100 g) was chopped into small pieces and was extracted 2 times with 1000 mL of ethanol for 72 h at room temperature. The filtration of the extracted solution and evaporation under reduced pressure yielded ethanol extracts (9.3 g). After the extract was thoroughly dried for complete removal of solvent, the dry extract was then stored in a deep freezer (−70°C).

#### 2.2. Bacterial Strains

Staphylococcal strains listed in Table 1 were 12 clinical isolates (MRSA) from Wonkwang University Hospital and the standard strain of MRSA ATCC 33591. Antibiotic susceptibility was determined from the size of the inhibition zone, in accordance with guidelines of Clinical & Laboratory Standards Institute (CLSI, 2010), and the used strains were defined as MRSA based on occurrence of the *meca* gene and their resistance to oxacillin [18]. β-Lactamase activity was also determined using the DrySlide Beta Lactamase test (Difco Laboratories, Detroit, MI, USA) according to manufacturer’s specification. After culturing on Mueller-Hinton agar (Difco Laboratories), the bacteria were suspended in Mueller-Hinton broth (Difco Laboratories) and used for inoculation. All MRSA strains used in this study are identified as MRSA [13].

#### 2.3. Disc Diffusion Method

As the first screening, the paper disc diffusion method was used to determine antibacterial activity, which is based on the method described previously [12, 19]. Sterile paper discs (6 mm; Toyo Roshi Kaisha, Japan) were loaded with 50 μL of different amounts (0.25, 0.5, and 1 mg) of the extracts dissolved in dimethyl sulfoxide (DMSO) and were left to dry for 12 h at 37°C in a sterile room. Bacterial suspensions were diluted to match the 0.5 MacFarland standard scale (approximately 1.5 × 10^8 CFU/mL) and they were further diluted to obtain a final inoculum. After Mueller-Hinton agar was poured into Petri dishes to give a solid plate and inoculated with 100 μL of suspension containing 1 × 10^8 CFU/mL of bacteria, the discs treated with extracts were applied to Petri dishes. Ampicillin and oxacillin were used as positive controls and paper discs treated with DMSO were used as negative controls. The plates were then incubated at 35°C for 24 h in an incubator (Vision Co., Seoul, Korea). Inhibition zone diameters around each disc were measured and recorded at the end of the incubation time.

#### 2.4. Determination of Minimum Inhibitory Concentrations (MICs)

MICs were determined by the agar dilution method, which is based on the method described previously [12, 20]. MICs of ampicillin and oxacillin were also determined. A final inoculum of 1 × 10^4 CFU/mL was spotted with a multipoint inoculator (Denley Instruments, Sussex, UK) onto agar plates. The plates were then incubated at 35°C for 24 h in the incubator (Vision Co., Seoul, Korea). The MIC was defined as the lowest concentration of extracts at which no visible growth was observed. The minimum concentration of

---

**Table 1: Bacterial strains used the test of antibacterial activity.**

| Strains         | Class     | *meca* gene | β-Lactamase activity | Antibiotic resistance pattern |
|-----------------|-----------|-------------|----------------------|------------------------------|
| *S. aureus* ATCC 33591 | MRSA      | +           | +                    | AM, OX, CF, E                |
| Clinical isolates |           |             |                      |                              |
| *S. aureus* (OMS 1) | MRSA      | +           | +                    | AM, OX                      |
| *S. aureus* (OMS 2) | MRSA      | +           | +                    | AM, OX, CF, E               |
| *S. aureus* (OMS 3) | MRSA      | +           | +                    | AM, OX, CF, E               |
| *S. aureus* (OMS 4) | MRSA      | +           | +                    | AM, OX, CF, E               |
| *S. aureus* (OMS 5) | MRSA      | +           | +                    | AM, OX, CF, E               |
| *S. aureus* (OMS 6) | MRSA      | +           | +                    | AM, OX, CF, E               |
| *S. aureus* (OMS 7) | MRSA      | +           | +                    | AM, OX, CF, E               |
| *S. aureus* (OMS 8) | MRSA      | +           | +                    | AM, OX, CF, E               |
| *S. aureus* (OMS 9) | MRSA      | +           | +                    | AM, OX, CF, E               |
| *S. aureus* (OMS 10)| MRSA      | +           | +                    | AM, OX, CF, E               |
| *S. aureus* (OMS 11)| MRSA     | +           | +                    | AM, OX                      |
| *S. aureus* (OMS 12)| MRSA     | +           | +                    | AM, OX                      |

+: positive; -: negative; AM: ampicillin; OX: oxacillin; CF: cephalothin; E: erythromycin.

OMS indicates Staphylococcal strains of Department of Oral and Maxillofacial Surgery, Wonkwang University Hospital.
Table 2: Nucleotide sequences of primer used for real-time PCR in this study.

| Gene  | Gene description                  | Primer sequences (5'-3')           |
|-------|-----------------------------------|------------------------------------|
| 16s rRNA | Normalizing internal standard     | Forward: ACTGGGATAACTTCGGGAAA      |
|       |                                   | Reverse: CGTTGCCTTGGTAAAGCC        |
| meCA  | Penicillin binding protein 2'     | Forward: GTTAGATTGGATCATAGCTGATT   |
|       |                                   | Reverse: TGTTGTGGATTATAGCTATGATT   |
| sea   | Staphylococcal enterotoxin A      | Forward: ATGGTGATTTATGGTTATGTTAT   |
|       |                                   | Reverse: TGTTGCACTTATGAGGTGTTT     |
| agrA  | Accessory gene regulator A        | Forward: CACTGTTGACTCCTGAGG      |
|       |                                   | Reverse: TGTTAATCATATGACGCTGTCG    |

Table 3: Antimicrobial activity (mm inhibition zones diameter) of extracts of Ulmus pumila against 12 methicillin-resistant Staphylococcus aureus (MRSA) and 1 standard MRSA.

| Strains                          | Zone of inhibition (mm) | Ulmus pumila (mg) | Ampicillin <sup>a</sup> | Oxacillin <sup>b</sup> |
|----------------------------------|-------------------------|-------------------|-------------------------|-------------------------|
| S. aureus (ATCC33591)            |                         |                   |                         |                         |
| Clinical isolates                | 0.25                    | 0.5               | 1                       | 10 µg                   | 1 µg                    |
| S. aureus (OMS 1)                | 10                      | 12                | 14                      | 10                      | ND                      |
| S. aureus (OMS 2)                | 11                      | 13                | 16                      | 12                      | 9                       |
| S. aureus (OMS 3)                | ND                      | 9                 | 14                      | 11                      | ND                      |
| S. aureus (OMS 4)                | 9                       | 11                | 15                      | 11                      | ND                      |
| S. aureus (OMS 5)                | 10                      | 14                | 16                      | 11                      | ND                      |
| S. aureus (OMS 6)                | 10                      | 12                | 14                      | 11                      | ND                      |
| S. aureus (OMS 7)                | 11                      | 15                | 17                      | 10                      | ND                      |
| S. aureus (OMS 8)                | ND                      | 10                | 14                      | 8                       | ND                      |
| S. aureus (OMS 9)                | 9                       | 13                | 15                      | 10                      | ND                      |
| S. aureus (OMS 10)               | 12                      | 15                | 18                      | 10                      | ND                      |
| S. aureus (OMS 11)               | 11                      | 14                | 17                      | 11                      | ND                      |
| S. aureus (OMS 12)               | 13                      | 16                | 19                      | 11                      | ND                      |

ND: no detected activity at this concentration; C: chloroform extract; B: n-butanol extract; M: methanol extract; A: aqueous extract.

<sup>a</sup> Ampicillin resistance ≤ 28 mm.

<sup>b</sup> Oxacillin resistance ≤ 10 mm.

extracts that inhibited 50% and 90% of the isolates tested was defined as MIC<sub>50</sub> and MIC<sub>90</sub>, respectively.

2.5. Real Time Polymerase Chain Reaction (PCR) Analysis. To determine the effect of U. pumila extract on gene expression, a real-time PCR assay was performed. The sub-MIC (32–125 µg/mL) of U. pumila extract was used to treat and culture MRSA ATCC 33591 for 24 h. Total RNA was isolated from MRSA by using Trizol reagent (Gibco-BRL) according to the manufacturer’s instructions and was treated with DNase to digest contaminated DNA. Then, cDNA was synthesized using a reverse transcriptase reaction (Superscript; Gibco-BRL). The DNA amplifications were carried out using an ABI-Priism 7000 Sequence Detection System with Absolute QPCR SYBR Green Mixes (Applied Bio systems Inc., Foster City, CA, USA). The primer pairs that were used in this study were described by previous reports [21–23] and are listed in Table 2. 16S rRNA was used as an internal control.

2.6. Phytochemical Screening. Phytochemical tests of extracts were performed as previously described [24, 25]. Mayer’s reagent was used for alkaloids, ferric chloride reagent for phenolic, Molisch test for glycosides, Biuret reagent for proteins, Mg-HCl reagent for flavonoids, Liebermann-Burchard reagent for steroids, and silver nitrate reagent for organic acids.

2.7. Statistical Analysis. All experiments were carried out in triplicate. Data were analyzed using the statistical package for social sciences (SPSS). Differences between means of the experimental and control groups were evaluated by the Student’s t-test.

3. Results

In this study, the antibiotic effect of ethanol extract of U. pumila on clinically isolated MRSA strain 12 and standard MRSA strain 1 (ATCC 33591) was examined. As a result of measuring antibacterial activity of U. pumila using the disc diffusion method, U. pumila showed antibacterial activities against all strains (Table 3). In all MRSA strains, 1 mg of
**Table 4:** Minimal inhibitory concentrations (MICs) of the *Ulmus pumila*, ampicillin, and oxacillin against 12 methicillin-resistant *Staphylococcus aureus* (MRSA) and 1 standard MRSA.

| Strains          | *Ulmus pumila* | MIC (μg/mL) | Ampicillin\(^1\) | Oxacillin\(^2\) |
|------------------|----------------|-------------|------------------|-----------------|
| *S. aureus* ATCC 33591 | 250            | 32          | 256              |
| Clinical isolates |                |             |                  |
| *S. aureus* (OMS 1) | 250            | 32          | 8                |
| *S. aureus* (OMS 2) | 250            | 32          | 4                |
| *S. aureus* (OMS 3) | 250            | 64          | 4                |
| *S. aureus* (OMS 4) | 250            | 64          | 4                |
| *S. aureus* (OMS 5) | 250            | 32          | 4                |
| *S. aureus* (OMS 6) | 125            | 64          | 16               |
| *S. aureus* (OMS 7) | 250            | 32          | 16               |
| *S. aureus* (OMS 8) | 250            | 32          | 8                |
| *S. aureus* (OMS 9) | 250            | 64          | 8                |
| *S. aureus* (OMS 10)| 125            | 4           | 4                |
| *S. aureus* (OMS 11)| 125            | 64          | 16               |
| *S. aureus* (OMS 12)| 125            | 64          | 4                |

\(^1\)Ampicillin resistance is an ampicillin MIC of ≥0.25 μg/mL.
\(^2\)Oxacillin resistance is an oxacillin MIC of ≥4 μg/mL.

*OMS* indicates Staphylococcal strains of Department of Oral and Maxillofacial Surgery, Wonkwang University Hospital.

*U. pumila* showed 14–19 mm of inhibition zone and 0.5 mg of *U. pumila* showed 9–16 mm of inhibition zone.

This experimental result was confirmed through MIC measurement (Table 4). Ethanol extract of *U. pumila* showed a range of MICs from 125 μg/mL to 250 μg/mL in all MRSA strains. In most strains, the growth of bacteria was inhibited noticeably from 250 μg/mL of *U. pumila* concentration. The MICs for ampicillin and oxacillin against MRSA clinical isolates, which had been used as the positive control, were 4–46 μg/mL and 4–16 μg/mL, respectively. These results showed that the MRSA strains isolated clinically have resistance to ampicillin and oxacillin. From this experimental result, these clinically isolated MRSA strains showed resistance to ampicillin or oxacillin. We performed real-time PCR analysis to examine the effect of sub-MIC (32–125 μg/mL) concentrations of *U. pumila* extract on the genetic expressions of virulence factors in standard MRSA (ATCC 33591). The expressions of mecA, sea, agrA, and sara were significantly decreased in MRSA when it was treated with the sub-MIC (63–125 μg/mL) concentrations of *U. pumila* extract (Figure 1).

As a result of phytochemical analysis of *U. pumila*, phenolics, steroids, and terpenoids were detected with a relatively high content; glycosides were detected with a medium level of content; flavonoids, peptides, and organic acids were detected with low content; but alkaloids were nearly never detected (Table 5).

**Table 5:** Phytochemical analysis of the ethanol extract of *Ulmus pumila*.

| Plant constituents | Ethanol extract |
|--------------------|-----------------|
| Alkaloids          | –               |
| Phenolics          | +++             |
| Flavonoids         | +               |
| Glycosides         | ++              |
| Peptides           | +               |
| Steroids, terpenoids | +++         |
| Organic acids      | +               |

+++: strong; ++: moderate; +: poor; –: absent.

*U. pumila* has been used for the treatment of infectious diseases in Korea. In this study, antibacterial activities of ethanol extract of *U. pumila* on clinically isolated 12 MRSA strains and 1 standard MRSA strain were examined.

Antibacterial activities of *U. pumila* were measured by using the disc diffusion method, which were then also confirmed through MIC measurements. *U. pumila* ethanol extract showed antibacterial abilities against all the strains, 12 strains of MRSA isolated clinically and 1 standard strain of MRSA. The fact that *U. pumila* extract suppresses growth of *S. aureus* could provide the scientific basis, that the extract had been used for the treatment of infectious diseases.

According to previous studies, *U. pumila* was known to contain steroidal chemicals such as β-Sitosterol, phytosterol, and stigmastanol; terpenoid chemicals such as friedelin, epifriedelanol, and taraxerol; phenolics such as tannin; and polysaccharides such as starch [16]. In this study, the phytochemical analysis of *U. pumila* showed a result of relatively high content of phenolics, steroids, and terpenoids. This result suggests that the antibacterial activity of *U. pumila* may be related with these chemicals. However, more
Additional researches are required to identify the antibacterial components in *U. pumila*.

Several mechanisms by which microorganisms can overcome antimicrobial agents are known. These mechanisms include production of drug insensitive enzymes, modification of targets for drug, and multidrug resistance pump which discharge the antimicrobial agents entered in bacterial cells. *mecA* is the typical multidrug resistance gene, and *fem, ilm,* and *sigB* are also the other multidrug resistance genes [26]. Recent studies reported that some medicinal plants contain multidrug resistance inhibitor that is to lower the MIC of antimicrobial agents [27]. In the present study, the effect of sub-MIC (32–125 μg/mL) concentrations of *U. pumila* extract on the genetic expression of *mecA* was determined by real-time PCR analysis. The expression of *mecA* was significantly decreased in standard MRSA (ATCC 33591) when it was treated with concentration higher than 64 μg/mL. Additional investigation is necessary to determine whether *U. pumila* may have multidrug resistance inhibitors.

A virulence factor gene, *sea*, encodes Staphylococcal enterotoxin A which is one of major virulence factors in MRSA [28]. Staphylococcal enterotoxin A is one cause of gastroenteritis in humans and acts as a superantigen. In this study, the sub-MIC concentrations of *U. pumila* extract significantly inhibited *sea* expression. *sea* gene expression in MRSA is regulated by global regulators such as *agr* and *sarA* genes [21]. In our study, sub-MIC (64–125 μg/mL) concentrations of *U. pumila* extract showed the inhibition of *agrA* and *sarA* expressions in MRSA. *agrA* encodes accessory gene regulator A which positively regulates exotoxin-encoding genes. *sarA* also upregulates expression of virulence factor genes. Previous research has shown that inhibition of *agrA* or *sarA* expression by some chemicals such as thymol or clindamycin reduces transcription of exotoxin-encoding genes [21]. In the present study, suppressive effect of *U. pumila* extract on *sea* gene expression may, in part, be related with the inhibitory effect of *U. pumila* extract on *agrA* and *sarA* expressions [29].

In conclusion, *U. pumila* has antibacterial effects against MRSA, which may be related to the phytochemicals such as phenolics, steroids, or terpenoids which are highly present in *U. pumila*.

---

**Figure 1:** Real-time PCR analysis of expression of several virulence factor genes. MRSA ATCC 33591 was cultured and treated with sub-MIC concentrations (32–125 μg/mL) of *U. pumila* extract, and real-time PCR analysis was then performed as described in the Section 2. *mecA, sea, sarA,* and *agrA* expressions were significantly inhibited at concentration higher than 64 μg/mL. Each value is expressed as a mean ± standard deviation. Significance was determined at *P* < 0.05 when compared with the control.
Conflict of Interests

The authors declare no conflict of interests.

Authors’ Contribution

Yong-Ouk You and Na-Young Choi contributed equally to this work.

Acknowledgment

This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (no. 2012R1A1A4A01012680).

References

[1] A. Al-Habib, E. Al-Saleh, A.-M. Safer, and M. Afzal, “Bacterialidal effect of grape seed extract on methicillin-resistant *Staphylococcus aureus* (MRSA),” *Journal of Toxicological Sciences*, vol. 35, no. 3, pp. 357–364, 2010.

[2] Y. O. You, K. J. Kim, B. M. Min, and C. P. Chung, “*Staphylococcus lugdunensis* a potential pathogen in oral infection,” *Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology*, vol. 88, no. 3, pp. 297–302, 1999.

[3] E. A. Morell and D. M. Balkin, “Methicillin-resistant *Staphylococcus aureus*: a pervasive pathogen highlights the need for new antimicrobial development,” *Yale Journal of Biology and Medicine*, vol. 83, no. 4, pp. 223–233, 2010.

[4] M. Dulan, F. Haamann, C. Peters, A. Schablon, and A. Nienhaus, “Mrsa prevalence in european healthcare settings: a review,” *BMC Infectious Diseases*, vol. II, article 138, 2011.

[5] C. Coughenour, V. Stevens, and L. D. Stetzenbach, “An evaluation of methicillin-resistant *Staphylococcus aureus* survival on five environmental surfaces,” *Microbial Drug Resistance*, vol. 17, no. 3, pp. 457–461, 2011.

[6] L. B. Rice, “Antimicrobial resistance in gram positive bacteria,” *American Journal of Infection Control*, vol. 34, pp. S11–S19, 2006.

[7] C. C. S. Fuda, J. F. Fisher, and S. Mobashery, “β-Lactam resistance in *Staphylococcus aureus*: the adaptive resistance of a plastic genome,” *Cellular and Molecular Life Sciences*, vol. 62, no. 22, pp. 2617–2633, 2005.

[8] H. Tsuchiya, M. Sato, T. Miyazaki et al., “Comparative study on the antibacterial activity of phytochemical flavanones against methicillin-resistant *Staphylococcus aureus*,” *Journal of Ethnopharmacology*, vol. 50, no. 1, pp. 27–34, 1996.

[9] S. Stefani and P. F. Vralardo, “Epidemiology of methicillin-resistant staphylococci in Europe,” *Clinical Microbiology and Infection*, vol. 9, no. 12, pp. 1179–1186, 2003.

[10] H. B. Kim, H.-G. Jang, H. J. Nam et al., “In Vitro Activities of 28 Antimicrobial Agents against *Staphylococcus aureus* Isolates from Tertiary-Care Hospitals in Korea: A Nationwide Survey,” *Antimicrobial Agents and Chemotherapy*, vol. 48, no. 4, pp. 1124–1127, 2004.

[11] R. R. Hafidh, A. S. Abdulamir, L. S. Vern et al., “Inhibition of growth of highly resistant bacterial and fungal pathogens by a natural product,” *Open Microbiology Journal*, vol. 5, pp. 96–106, 2011.

[12] K.-J. Kim, H.-H. Yu, S.-I. Jeong, J.-D. Cha, S.-M. Kim, and Y.-O. You, “Inhibitory effects of *Caesalpinia sappan* on growth and invasion of methicillin-resistant *Staphylococcus aureus*,” *Journal of Ethnopharmacology*, vol. 91, no. 1, pp. 81–87, 2004.

[13] K.-J. Kim, H.-H. Yu, J.-D. Cha, S.-J. Seo, N.-Y. Choi, and Y.-O. You, “Antibacterial activity of *Curcuma longa* L. against methicillin-resistant *Staphylococcus aureus*,” *Phytoterapy Research*, vol. 19, no. 7, pp. 599–604, 2005.

[14] H.-H. Yu, K.-J. Kim, J.-D. Cha et al., “Antimicrobial activity of berberine alone and in combination with ampicillin or oxacillin against methicillin-resistant *Staphylococcus aureus*,” *Journal of Medicinal Food*, vol. 8, no. 4, pp. 454–461, 2005.

[15] T. W. Lee, S. N. Kim, U. K. Jee, and S. J. Hwang, “Anti-wrinkle effect of pressure sensitive adhesive hydrogel patches containing ulmi cortex extract,” *Journal of Korean Pharmaceutical Sciences*, vol. 34, pp. 193–199, 2004.

[16] K. Y. Jeong and M. L. Kim, “Physiological activities of *Ulms pumila* L. Extracts,” *The Korean Journal of Food Preservation*, vol. 19, pp. 104–109, 2012.

[17] J. K. Kim, *Illustrated Natural Drugs Encyclopedia*, Namsandang, Seoul, Korea, 1989.

[18] F. Wallet, M. Roussel-Delvallez, and R. J. Courcol, “Choice of a routine method for detecting methicillin resistance in staphylococci,” *The Journal Antimicrobial Chemotherapy*, vol. 37, no. 3, pp. 901–909, 1996.

[19] N. A. A. Ali, W.-D. Jülich, C. Kusnick, and U. Lindequist, “Screening of Yemeni medicinal plants for antibacterial and cytotoxic activities,” *Journal of Ethnopharmacology*, vol. 74, no. 2, pp. 173–179, 2001.

[20] S.-C. Chang, Y.-C. Chen, K.-T. Luh, and W.-C. Hsieh, “In vitro activities of antimicrobial agents, alone and in combination, against Acinetobacter baumannii isolated from blood,” *Diagnostic Microbiology and Infectious Disease*, vol. 23, no. 3, pp. 105–110, 1995.

[21] J. Qiu, X. Zhang, M. Luo et al., “Subinhibitory concentrations of perilla oil affect the expression of secreted virulence factor genes in *Staphylococcus aureus*,” *PLoS ONE*, vol. 6, no. 1, article e16160, 2011.

[22] P. Jia, Y. J. Xue, X. J. Duan, and S.-H. Shao, “Effect of cinnamaldehyde on biofilm formation and sarA expression by methicillin-resistant *Staphylococcus aureus*,” *Letters in Applied Microbiology*, vol. 53, no. 4, pp. 409–416, 2011.

[23] A. E. Rosato, W. A. Craig, and G. L. Archer, “Quantitation of mecA transcription in oxacillin-resistant *Staphylococcus aureus* clinical isolates,” *Journal of Bacteriology*, vol. 185, no. 11, pp. 3446–3452, 2003.

[24] P. J. Houghton and A. Raman, *Laboratory Handbook for the Fractionation of Natural Extracts*, Chapman & Hall, London, UK, 1998.

[25] W. S. Woo, *Experimental Methods for Phytochemistry*, Seoul National University Press, Seoul, Korea, 2001.

[26] S. Shiota, M. Shimizu, T. Mizushima et al., “Marked reduction of the minimum inhibitory concentration (MIC) of β-lactams in methicillin-resistant *Staphylococcus aureus* produced by epicatechin gallate, an ingredient of green tea (*Camellia sinensis*),” *Biological and Pharmaceutical Bulletin*, vol. 22, no. 12, pp. 1388–1390, 1999.

[27] F. R. Stermitz, P. Lorenz, J. N. Tawara, L. A. Zenewicz, and K. Lewis, “Synergy in a medicinal plant: antimicrobial action of berberine potentiated by 5'-methoxyhydrocarchin, a multidrug pump inhibitor,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 97, no. 4, pp. 1433–1437, 2000.
[28] J. Qiu, D. Wang, H. Xiang et al., “Subinhibitory concentrations of thymol reduce enterotoxins A and B and alpha-hemolysin production in Staphylococcus aureus isolates,” PloS One, vol. 5, no. 3, article e9736, 2010.

[29] L. I. Kupferwasser, M. R. Yeaman, C. C. Nast et al., “Salicylic acid attenuates virulence in endovascular infections by targeting global regulatory pathways in Staphylococcus aureus,” Journal of Clinical Investigation, vol. 112, no. 2, pp. 222–233, 2003.